| Identification | Back Directory | [Name]
Depatuxizumab Mafodotin | [CAS]
1585973-65-4 | [Synonyms]
Depatuxizumab Mafodotin
Depatuxizumab mafodotin (anti-EGFR) |
| Hazard Information | Back Directory | [Uses]
Depatuxizumab mafodotin is an antibody-drug conjugate (ADC) that specifically targets the epidermal growth factor receptor (EGFR). Depatuxizumab mafodotin can be used for cancer research[1]. | [References]
[1] Goss G D, et al. Efficacy and safety results of depatuxizumab mafodotin (ABT‐414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor[J]. Cancer, 2018, 124(10): 2174-2183. DOI:10.1002/cncr.31304 |
|
|